Australian Institute of Tropical Health & Medicine
Brian Cooke
- Adjunct Professor
- brian.cooke@jcu.edu.au
Amanda Murphy
- Senior Research Fellow
- amanda.murphy@jcu.edu.au
Tessa Knox
- Principal Research Fellow
- tessa.knox@jcu.edu.au
Justin Sexton
- Adjunct Research Fellow
- justin.sexton1@jcu.edu.au
Adeshina Adekunle
- Adjunct Research Fellow
- adeshina.adekunle@jcu.edu.au
Brogan Amos
- Adjunct Research Fellow
- brogan.amos@jcu.edu.au
Rachael Ryan
- Postdoctoral Research Fellow
- rachael.ryan1@jcu.edu.au
Emma McBryde
- Adjunct Professor
- emma.mcbryde@jcu.edu.au
Juergen Reichardt
- Adjunct Professor
- juergen.reichardt@jcu.edu.au
Tanya Russell
- Principal Research Fellow
- tanya.russell@my.jcu.edu.au
An integrated, multi-model bio-layer interferometry facility (Old ID 26412)
Norelle Daly
01 Jan 2020 - 31 Dec 2020
Biomolecular interaction research in Australia is currently constrained by low-throughput, labour intensive techniques that impede research progress and often forces it overseas. This project aims to develop a world class, integrated, multi-node bio-layer interferometry facility. This project expects to generate new knowledge in diverse areas of research ranging from biodiscovery to agricultural vaccine technology. Using biolayer interferometry, the leading-edge biomolecular interaction technique will provide significant benefits by developing high-significant assay techniques, thus enabling diverse streams of national benefit research and propelling Australia to the forefront of biomolecular interaction research.
Development of a Vector Management Programme at Intellectual Ventures Labs (Old ID 22721)
Tom Burkot
16 May 2016 - 15 May 2017
To develop support for and development of a vector management strategy and potential program for the Global Health Technologies Organization of Intellectual Ventures Labs. Activities will be development of a mosquito monitoring and control programs with an initial focus on malaria vectors including development of target product profiles for potential interventions and their development towards field evaluations.
Envenomation, first aid and critical care of tropical jellyfish stings (Old ID 21777)
Jamie Seymour
01 Dec 2014 - 31 Dec 2017
The first component of our research examines the use of vinegar for envenomings, and aims to provide evidence as to whether vinegar is beneficial or worsens an envenomation. The second component of our research examines whether the lethal effects of Chironex fleckeri venom are transient and whether there is a return of cardiac function. This has implications for good, effective and prolonged resuscitation. In the final component of our research, treatment modalities for Irukandji syndrome, has the potential to directly save lives and decrease the length of stay in hospital of envenomed victims as well as reducing the pain associated with the syndrome.
Tools to control Schistosomiasis (Old ID 22805)
Alex Loukas
01 Jul 2016 - 30 Jun 2019
We will construct a proteome microarray of Schistosoma haematobium proteins to identify vaccine and diagnostic antigens for African schistosomiasis. Vaccine antigens will be prioritised and tested in collaboration with the Sabin Vaccine Institute, and diagnostic antigens will be developed in a funded partnership with Merck. Merck are also contributing funds to this project.
Unravelling the correlates of protection against tuberculosis – Stage II (Old ID 26979)
Andreas Kupz
01 Jan 2020 - 28 May 2027
Tuberculosis is a major global public health problem and continues to cause significant morbidity and mortality due to the low efficiency of the only licensed anti-tuberculosis vaccine, BCG. This project aims to unravel the immunological correlates that mediate protection against tuberculosis. Using high-dimensional immune profiling and microbiome analyses we will compare immune responses to BCG vaccination with Mycobacterium tuberculosis infection in children in the Torres Strait.
Exploring new treatments for box jellyfish envenomation (Old ID 22220)
Michael Smout
01 Jul 2016 - 30 Jun 2017
The best medical treatment for big box jellyfish envenoming is uncertain. To improve future treatments, we will explore the cardiotoxic mechanisms of the venom and screen for new drug and antivenom treatments using our hi-throughput real-time cardiomyocyte (heart muscle cell) assay.
Secreted exosome-like vesicles from the carcinogenic liver fluke (Old ID 21477)
Alex Loukas
01 Jan 2015 - 31 Dec 2018
Parasitic worms secrete molecules from their oral openings and outer surfaces as they feed and reproduce inside their human hosts. These molecules are referred to as Excretory/Secretory (ES) products, akin to our saliva and sweat. These ES products represent the molecular interface of the host-parasite relationship. We recently showed that ES products from the parasitic liver fluke, a worm that is a major cause of liver cancer throughout parts of SE Asia, are taken up by cells lining the human bile ducts, the site where the parasite resides for years at a time. Until now the mechanisms by which these molecules are taken up and internalised by host cells was unknown. We now show that liver fluke ES proteins enter into human bile duct cells by forming small cell-like vesicles called exosomes. Once the flukes exosomes get inside human bile duct cells they induce a series of changes inside the cell which typifies the early stages of cancer formation. We now propose to better characterise the process of exosome uptake by human bile duct cells and exploit this information to discover vaccines to combat this carcinogenic infection and develop new tools to identify people who are most at risk of developing cancer from liver fluke infection.
New strategies for improved tuberculosis vaccines (Old ID 23218)
Andreas Kupz
01 Jan 2018 - 31 Dec 2021
Tuberculosis is a major global public health problem and continues to cause significant morbidity and mortality due to the low efficiency of the only licensed anti-tuberculosis vaccine, BCG. This project aims to produce novel, highly efficacious vaccination regimens against tuberculosis, especially pulmonary tuberculosis, which is currently the most difficult manifestation of infection to control. The results of this project have the potential to not only save millions of lives in the developing world but also to decrease socioeconomic burden of tuberculosis, particularly in the context of HIV co-infection.
Modelling future testing needs for SARS-CoV-2 (Old ID 27032)
Emma McBryde
21 Oct 2020 - 22 Oct 2020
The Project will enable greater understanding of the current and projected future testing demand for severe acute respiratory acute syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus 2019 (COVID-19) in Australia. The scope of this project is limited to assessing the demand for laboratory based, or near patient point-of-care, polymerase chain reaction (PCR) testing, the gold standard test to diagnose COVID-19.
New Equipment for TB vaccine development - GNT900485 (Old ID 24799)
Andreas Kupz
01 Jan 2017 - 31 Dec 2018
Tuberculosis is a major global public health problem and continues to cause significant morbidity and mortality due to the low efficiency of the only licensed anti-tuberculosis vaccine, BCG. This equipment will facility investigations into novel mechanisms for improved TB vaccines. Tissue dissociation is an integral part of Flow Cytometry and is used on a daily basis in my lab. The gentleMACS™ Octo Dissociator with Heaters is a benchtop instrument capable of fully automated and standardised tissue dissociation or homogenisation of up to eight samples. The instrument allows the user to create user-defined programs for almost any biological material. Using a Gentle MACS Dissociator enhances cell viability, cell yield and significantly decreases the time needed to process organs.
Cross-sectional association of seafood consumption, polyunsaturated fatty acids and depressive symptoms in two Torres Strait communities
- 2020
- Taylor & Francis
- Researchers:Zoltan SarnyaiRobyn McDermott
The importance of heterogeneity to the epidemiology of tuberculosis
- 2019
- University of Chicago Press
- Researchers:Emma McBryde
Title:
Ria de Groot prize
Start Date:
01 Jan 2010
Start Date:
01 Jan 2022
End Date:
01 Jan 2024
Start Date:
01 Jan 2022
End Date:
01 Jan 2024
Start Date:
01 Jan 2021
Start Date:
01 Jan 2019
Start Date:
01 Jan 2019
Title:
Frontiers in Immunology